Acute myocardial infarction (AMI) in individuals with type 2 diabetes mellitus (T2DM) remains associated with a significantly elevated early risk of negative outcomes compared to non-diabetic individuals, even in the current day. Diabetes correlates with increased coronary atherosclerosis, endothelial dysfunction, a pro-thrombotic environment, autonomic dysfunction, and a higher prevalence of comorbidities — elements that result in elevated in-hospital complications (heart failure, arrhythmias, cardiogenic shock) and a poorer short-term prognosis following acute myocardial infarction (AMI). Extensive observational data and current reviews consistently underscore diabetes as a significant factor contributing to adverse outcomes post- AMI, necessitating enhanced risk stratification and rigorous care in this population.[1] In actual emergency admissions, metabolic abnormalities upon presentation are particularly revealing since they are easily accessible, cost-effective, and indicative of both chronic risk and acute stress physiology. Admission hyperglycemia, including stress hyperglycemia, is consistently linked to poorer short-term outcomes in acute myocardial infarction (AMI), manifesting as increased rates of heart failure, arrhythmias, cardiogenic shock, major adverse cardiovascular events (MACE), and mortality, occasionally surpassing the impact of pre-existing diabetes. Admission glucose and associated glycemic metrics are clinically significant for the early triage and monitoring intensity in AMI patients with T2DM.[2–4]

 Likewise, serum uric acid is progressively acknowledged as a practical biomarker associated with oxidative stress, inflammation, endothelial dysfunction, and compromised cardiac perfusion. Numerous studies indicate a correlation between elevated uric acid levels and negative outcomes following myocardial infarction, including increased short-term mortality and deteriorated clinical status (e.g., elevated Killip class/heart failure severity), implying that it may provide additional prognostic value when utilised in conjunction with standard clinical indicators. Assessing uric acid levels in acute myocardial infarction patients with type 2 diabetes mellitus might enhance early risk prediction in standard tertiary-care environments.[5,6]

Dyslipidaemia (total cholesterol, LDL-C, HDL-C, triglycerides) is pivotal to atherosclerotic risk and secondary prevention; nevertheless, lipid profiles during an acute myocardial infarction can be intricate due to acute-phase alterations, pre- treatment influences, and persistent "residual risk" despite therapeutic interventions. Documenting lipid parameters upon admission and correlating them with short-term problems might enhance evidence-based management and quality improvement, as early in-hospital choices frequently involve commencing or escalating cholesterol- lowering treatment and establishing discharge objectives.[7,8] Indian ACS registries indicate a significant and increasing prevalence of diabetes among AMI admissions, correlating with poorer early outcomes. However, there is a paucity of detailed, hospital-level evidence from numerous government tertiary centres, especially regarding the relationship between admission levels of uric acid, glucose, and cholesterol and their impact on short-term complications and prognosis. This study conducted among admitted patients at GGH, Guntur aims to generate locally pertinent data to (1) quantify the metabolic risk profile within the patient population, (2) ascertain the metabolic markers that most accurately predict in- hospital complications, and (3) inform practical protocols for early monitoring and targeted risk mitigation in a resource-limited public hospital environment.

AIMS & OBJECTIVES

1. To know about serum uric acid level and impact on short term mortality.
2. On admission glucose and total cholesterol levels and their impact on severity of AMI along with serum uric acid elevation.
3. To study the atypical presentations in DM presenting with acute myocardial infarction
4. To assess the prognostic significance of serum Uric acid level in Acute Myocardial Infarction in type 2 diabetics.
5. To evaluate serum Uric acid levels with incidence of cardiac failure in diabetes with AMI
6. . 6. To validate the relation between Quantitative serum Uric acid level on admission and Killip’s class status on AMI in type 2 DM.
7. To know whether the incidence of Arrhythmias bears a relation with serum Uric acid level in Acute Myocardial Infarction.

Study Design This was an observational prospective study. Duration of the Study The study was conducted from March 2024 to August 2025. Sample Size A total of 100 patients were included in the study. Source of Data The data were collected from all patients with a previous history of type 2 diabetes mellitus presenting with Acute ST Elevation Myocardial Infarction. Inclusion Criteria Patients were enrolled in the research if they met the criteria for a definitive diagnosis of Acute ST Elevation Myocardial Infarction, which encompassed the following: ● A history of standard retrosternal compressive chest discomfort or unusual manifestations in individuals with type 2 diabetes mellitus persisting for over 30 minutes and unrelieved by rest or nitrates. ● Occurrence of unusual symptoms in individuals with type 2 diabetes mellitus. ● Characteristic electrocardiographic alterations of Acute ST Elevation Myocardial Infarction include ST segment or T wave modifications in two adjacent leads. Exclusion Criteria Patients were excluded from the study if they had: 1. Elevated renal parameters. 2. Gout. 3. History of chronic alcoholism. 4. Previous history of ischemic heart disease and were on aspirin therapy. 5. Newly diagnosed diabetes mellitus. 6. Hypertension or were on diuretic therapy. 7. Hematological malignancy or hypothyroidism. Method of Study This prospective study aimed to evaluate the predictive significance of metabolic variables, namely serum uric acid, total cholesterol, and blood glucose levels, after Acute Myocardial Infarction in patients with type 2 diabetes mellitus, and to link these parameters with short-term sequelae. A total of 100 individuals with type 2 diabetes mellitus and Acute Myocardial Infarction were included. Patients with normal serum uric acid levels constituted the control group, whereas those with increased serum uric acid levels comprised the study group. The incidence of complications and short-term outcomes was compared between the two groups. Ethical Considerations All patients provided informed permission prior to their enrolment in the trial. Consent was also acquired for the collection and retention of patient pictures. The confidentiality of patient information was rigorously upheld. The uncertainties of patients and their carers were elucidated to prevent any misunderstanding. The study's academic goal was elucidated prior to enrolment. Patients were notified that they might withdraw from the trial at any point throughout the research duration. No unethical techniques were employed, and participation in the study did not entail any physical discomfort or social humiliation.

TABLE 1: AGE INCIDENCE

Table 2 : SEX INCIDENCE

Table 3 : CONTROL AND STUDY POPULATION

Table 4: DISTRIBUTION OF PATIENTS ACCORDING TO URIC ACID LEVEL & SEX – IN TOTAL POPULATION

Table 5 : STATISTICAL SIGNIFICANCE

Table 6: KILLIP CLASS IN HIGH SERUM URIC ACID POPULATION (STUDY GROUP)

Table 7: KILLIP CLASS IN CASES WITH CONCURRENT ELEVATION OF URIC ACID , TOTAL CHOLESTEROL AND BLOOD SUGAR (n = 36)

Table 8 : KILLIP CLASS IN NORMAL SERUM URIC ACID POPULATION (CONTROL POPULATION)

Table 9 : TYPE OF INFARCTION

Table 10 : INCIDENCE OF HEART FAILURE IN TOTAL POPULATION

Table 11 : HEART FAILURE ACCORDING TO SEX

Table 12 : PROPORTION OF HEART FAILURE CONTRIBUTED BY PATIENTS WITH NORMAL & HIGH SERUM URIC ACID LEVEL

Table 13 : INCIDENCE OF HEART FAILURE IN PATIENTS WITH HIGH SERUM URIC ACID LEVEL (STUDY GROUP)

Table 14 : HEART FAILURE IN HYPERURICEMICS , HYPERGLYCEMICS & DYSLIPIDEMICS

Table 15 : INCIDENCE OF HEART FAILURE IN PATIENTS WITH NORMAL SERUM URIC ACID LEVEL (CONTROL GROUP)

Table 16 :ECHOCARDIOGRAM ANALYSIS

Table 17 : INCIDENCE OF ARRHYTHMIAS (IN TOTAL POPULATION)

Table 18 : ARRHYTHMIAS ACCORDING TO SEX

Table 19 : PROPORTION OF ARRHYTHMIAS CONTRIBUTED BY PATIENTS WITH NORMAL & HIGH SERUM URIC ACID LEVEL

Table 20 : INCIDENCE OF ARRHYTHMIAS IN PATIENTS WITH HIGH SERUM URIC ACID LEVEL (STUDY GROUP)

Table 21 : INCIDENCE OF ARRHYTHMIAS IN PATIENTS WITH NORMAL URIC ACID LEVEL (CONTROL GROUP)

Table 22 : INCIDENCE OF MORTALITY (IN TOTAL POPULATION)

Table 23 : MORTALITY ACCORDING TO SEX

Table 24 : PROPORTION OF MORTALITY CONTRIBUTED BY PATIENTS WITH NORMAL & HIGH SERUM URIC ACID LEVEL

Table 25 : INCIDENCE OF MORTALITY IN PATIENTS WITH HIGH SERUM URIC ACID LEVEL (STUDY GROUP)

Table 26 : MORTALITY IN AGE GROUP

Table 27 : PATIENTS PRESENTATION ON ADMISSIONS

Acute myocardial infarction (AMI) remains a primary cause of morbidity and death globally, with a particularly significant impact on those with type 2 diabetes mellitus. Diabetes not only elevates the incidence of coronary artery disease but also markedly affects the clinical manifestation, severity, and short-term prognosis after an acute coronary event. Diabetic people frequently exhibit greater coronary involvement, delayed symptom detection, and an increased prevalence of related metabolic disorders, all of which lead to a worse prognosis relative to non-diabetic persons. In this context, comprehending the variables that influence early outcomes following AMI is essential for appropriate risk categorisation and treatment. Metabolic abnormalities are the fundamental pathophysiological basis connecting diabetes and negative cardiovascular outcomes. Hyperglycemia, dyslipidaemia, and disrupted purine metabolism are not only incidental characteristics in diabetic patients; instead, they actively engage with ischaemic, inflammatory, and neurohormonal mechanisms activated during acute myocardial infarction (AMI). Acute stress-induced hyperglycemia indicates both prior glycaemic regulation and the severity of the physiological stress response, whereas dyslipidaemia signifies chronic atherogenic exposure that contributes to plaque instability and infarct load. Increased blood uric acid, acknowledged as a sign of oxidative stress, inflammation, and compromised renal and endothelial function, has surfaced as a possible indication of disease severity in acute coronary syndromes. The first clinical trajectory of acute myocardial infarction is predominantly influenced by the degree of myocardial damage and the organism's capacity to adapt to the abrupt decline in heart function. This is clinically evidenced by characteristics like Killip class, onset of heart failure, left ventricular systolic dysfunction, arrhythmias, and in-hospital mortality. In diabetic patients, these compensatory mechanisms are frequently diminished due to pre-existing cardiac dysfunction, microvascular disease, autonomic instability, and renal involvement. The identical ischaemic insult may result in disproportionately severe clinical outcomes, highlighting the necessity to discover indicators that might forecast early deterioration. Although individual metabolic parameters have been investigated concerning AMI outcomes, there is a notable scarcity of data analysing their cumulative impact, especially within diabetic populations. In standard clinical practice, uric acid, blood glucose, and cholesterol levels are commonly accessible tests; nonetheless, their combined prognostic importance is frequently overlooked during the acute phase of myocardial infarction. Assessing these factors collectively yields a more comprehensive understanding of the metabolic and inflammatory environment around AMI, perhaps enhancing insight into short-term risk compared to any individual parameter alone. This study aims to assess the influence of critical metabolic factors—serum uric acid, blood glucose, and cholesterol—on the prognosis and short-term sequelae of acute myocardial infarction in individuals with type 2 diabetes mellitus. The study seeks to elucidate the relevance of these metabolic anomalies in early risk stratification by connecting them with clinically significant outcomes, including Killip class, heart failure, echocardiographic left ventricular function, arrhythmias, and death. Establishing this framework is crucial prior to analysing the subsequent detailed discourse, as it positions metabolic disturbances not only as separate laboratory results, but as fundamental elements of the pathophysiology influencing early outcomes in diabetic individuals with acute myocardial infarction. How our study cohort looks, and why it matters clinically In our sample of 100 patients with acute myocardial infarction and type 2 diabetes, the highest prevalence was observed in the 51–60 year age group (40%), with a mere 3% of instances occurring in individuals over 70 years. The "middle-aged predominance" aligns with current AMI epidemiology in South Asian/Asian contexts, where cardiometabolic risk accumulates earlier, influencing the understanding of short-term complications: when AMI manifests within this age range, it is frequently propelled by a concentrated aggregation of metabolic abnormalities rather than age alone. The sex distribution in the overall cohort was nearly equitable (54% men, 46% women), which holds clinical significance as various AMI registries indicate that while women may present later or exhibit distinct risk profiles, the severity at presentation (e.g., Killip class) is a critical factor influencing early outcomes, rather than sex itself. The almost equal sex distribution in our dataset offers a solid foundation for analysing metabolic predictors without one sex skewing the results. Hyperuricemia in AMI with T2DM: distribution and statistical separation from controls A significant finding in our research is the distinct biochemical differentiation between groups: the hyperuricemia study group exhibited a mean uric acid level of 8.05 ± 0.71 mg/dL, compared to 5.09 ± 1.01 mg/dL in the control group (p < 0.0001). This size and direction closely resemble traditional AMI uric acid observational studies that shown a robust correlation between elevated blood uric acid levels and clinical severity at presentation (including Killip class). A pertinent comparison is a 100- patient AMI research by Nadkar et al. that explicitly documented a strong correlation between blood uric acid levels and Killip categorisation in AMI.[9] In the analysis of sex-specific uric acid distributions within the entire population, both males and females exhibit elevated levels; however, females predominantly concentrate in the 7.0–8.9 mg/dL range (14 and 12 cases, respectively). This observation underscores that hyperuricemia in diabetics is not exclusively indicative of males—factors such as renal handling, diuretic use, insulin resistance, and inflammatory status can contribute to urate elevation in both sexes. Hyperuricemia and hemodynamic severity: Killip class is where the prognostic story begins The most clinically significant link is the increase in Killip classes among hyperuricemic individuals. In the high uric acid cohort, 36 out of 56 (64.3%) were classified as Killip III–IV, in contrast to 8 out of 44 (18.2%) in the normouricemic controls. In terms of impact magnitude, hyperuricemia in our population was linked to an approximately 3.54-fold increased chance of presenting in Killip III–IV (RR = 3.54). This is closely correlated with several previous studies that associate uric acid with Killip class, left ventricular failure, and mortality indicators in acute myocardial infarction. Kojima et al. (2005) indicated that hyperuricemia during acute myocardial infarction correlates with the onset of heart failure, and that the integration of Killip class with serum uric acid enhances prognostic differentiation. Recent clinical datasets further corroborate that elevated urate levels correlate with increased Killip class and decreased LVEF, despite variations in mortality outcomes based on cohort composition and adjustments.[10,11] Significantly, several studies indicate that the uric-acid signal may interact with Killip strata instead of exerting a uniform effect across all severity levels. Liu et al. (2017) indicated that hyperuricemia elevated mortality in STEMI patients classified as Killip I, with a less definitive incremental effect observed in Killip II–IV. This interaction concept reinforces our interpretation: urate serves as a robust marker of adverse biological conditions and may be especially valuable for risk stratification in earlier clinical stages, whereas in cases of overt shock or pulmonary oedema, haemodynamic failure may predominate in determining prognosis.[12] The “metabolic triad” (urate + glucose + cholesterol) amplifies severity A key finding in our studies is the effect of clustered metabolic insults. Of the 36 patients exhibiting simultaneous elevations in uric acid, total cholesterol, and blood glucose, 26 (72.2%) were classified as Killip III–IV, and 28 (77.8%) progressed to heart failure. This is clinically intuitive and robustly substantiated by extensive evidence: hyperglycemia exacerbates infarct outcomes through endothelial dysfunction, oxidative stress, pro-thrombotic alterations, and compromised microvascular reperfusion; dyslipidaemia enhances plaque burden and susceptibility; and hyperuricemia indicates oxidative/inflammatory stress and impaired renal processing—collectively forming a “high-risk metabolic phenotype.” Despite ongoing debates on the independent causative nature of each factor vs its role as a marker, meta-analytic data consistently demonstrates that hyperuricemia predicts negative outcomes in populations with acute coronary syndrome/myocardial infarction, including short-term mortality and major adverse cardiovascular events. This corroborates our triadic observation: the grouping is non-random and amplifies danger.[13] Heart failure: our strongest short-term complication signal Heart failure was observed in 44% of the whole cohort (44/100), with hyperuricemia disproportionately contributing: 36 of the 44 HF patients originated from the hyperuricemic group. The incidence of within-group hazards was 36 out of 56 (64.3%) for hyperuricemic patients compared to 8 out of 44 (18.2%) for normouricemic controls, indicating an approximate 3.54-fold increased risk of heart failure in hyperuricemic patients (RR = 3.54). This aligns well with the mechanistic and observational literature connecting uric acid to left ventricular dysfunction and heart failure development post-acute myocardial infarction, including the seminal findings by Kojima et al. and later cohorts demonstrating relationships with reduced left ventricular ejection fraction and elevated Killip class. Meta-analytic research in ACS corroborates urate as a predictive biomarker for mortality and major adverse cardiovascular events, which frequently present first as pump failure and shock physiology.[10,13] Echo-correlated LV dysfunction: hyperuricemia tracks myocardial damage severity The echocardiographic distribution robustly corroborates the clinical heart failure diagnosis. Among hyperuricemic patients, only 4 out of 56 had normal left ventricular systolic function, whereas 44 out of 56 demonstrated moderate to severe dysfunction (26 moderate and 18 severe). Among the controls, 28 out of 44 had normal left ventricular function, whereas only 9 out of 44 demonstrated moderate to severe dysfunction. This trend aligns with previous data indicating that elevated urate levels correlate with reduced LVEF and worse clinical outcomes following AMI. Within the context of our investigation, hyperuricemia in our cohort likely signifies individuals with a greater ischaemic load, increased microvascular dysfunction, or elevated systemic oxidative stress—each of which plausibly correlates with worse left ventricular performance during the acute phase.[14] Arrhythmias: increased proportion with hyperuricemia, and the glycemia link Arrhythmias manifested in 12% of cases (12/100). Hyperuricemia was responsible for 9 out of the 12 occurrences (75%). In the hyperuricemic group, arrhythmias occurred in 16.1% (9/56) of cases, compared to 6.8% (3/44) in the normouricemic controls (RR = 2.36). Although lower sample sizes diminish statistical confidence, the observed trend aligns with biological plausibility: exacerbated left ventricular failure, elevated Killip class, electrolyte and renal disturbances, and increased catecholamine and inflammatory activity all elevate the likelihood of arrhythmias. Hyperglycemia is a significant enhancer of arrhythmia risk in acute myocardial infarction (AMI). A comprehensive study and meta-analysis examining the correlation between admission hyperglycemia and arrhythmias in acute myocardial infarction corroborates this link, consistent with our "triad" group, which frequently had severe heart failure and elevated Killip scores. In summary, whereas urate serves as the grouping biomarker in our design, the cumulative metabolic stress, particularly acute hyperglycemia, likely induces electrical instability in conjunction with pump failure.[15] Mortality: hyperuricemia concentrates deaths in our cohort The overall mortality rate was 15% (15 out of 100). Hyperuricemia was responsible for 12 out of 15 fatalities (80%). The death rate within the group was 21.4% (12/56) among hyperuricemic patients compared to 6.8% (3/44) in the control group (RR = 3.14). This corresponds with a significant body of research indicating that increased uric acid predicts worse outcomes following ACS/MI, encompassing extensive observational cohorts and meta-analyses. Multiple individual studies indicate correlations between elevated urate levels and mortality/left ventricular failure in acute myocardial infarction, aligning with the trends observed in our dataset. While certain cohorts indicate diminished mortality associations post-adjustment (implying confounding factors such as renal function, infarct size, or pre-existing comorbidities), they frequently reaffirm correlations with reduced LVEF and elevated Killip class, which are direct contributors to early mortality—reinforcing our observation that heart failure/left ventricular dysfunction is the primary mechanism through which the urate signal manifests in the short term.[16,17] Blood sugar in AMI with diabetes: why “admission hyperglycemia” still matters in T2DM Acute glycaemic increase at presentation in diabetes is consistently linked to poorer prognosis in acute myocardial infarction, however the association may be intricate, occasionally characterised as U-shaped in diabetic patients. A substantial body of research indicates that admission hyperglycemia correlates with increased short- term mortality and adverse outcomes in acute myocardial infarction populations, with newer analysis especially investigating whether the prognostic implications vary according to known diabetes status. Our triad results (elevated HF and significant Killip proportion) align with this evidence: acute hyperglycemia in AMI is not merely a “laboratory anomaly”—it signifies a stress response and exacerbates microvascular dysfunction, hampers reperfusion, enlarges infarct size, and creates an arrhythmogenic environment, all of which correlate with increased Killip class, HF, and mortality risk.[18] Cholesterol and the early AMI paradox: interpreting “cholesterol” as risk vs acute prognostic marker Cholesterol serves as a chronic causal risk factor for atherosclerosis; however, in the context of acute myocardial infarction, numerous extensive datasets indicate a "lipid paradox," wherein diminished LDL-C or total cholesterol levels upon admission correlate with increased short-term mortality. This association is likely confounded by factors such as inflammation, frailty, malnutrition, or severity of illness, alongside the established observation that lipid levels may decline during the acute inflammatory phase. Research elucidating this contradiction and its relationship with Killip severity offers a valuable perspective for our dissertation issue, as it warns against interpreting a singular acute lipid measurement as either "protective" or "harmful" devoid of context.[19] This interpretation of our data supports a clinically informed stance: dyslipidaemia continues to be a primary etiological factor, however acute lipid levels may be skewed by the inflammatory state associated with acute myocardial infarction (AMI). Therefore, the prognostic contribution of “cholesterol” in our triad is best understood as part of a broader metabolic burden—especially when combined with hyperglycemia and hyperuricemia—rather than as an isolated linear predictor measured during the acute phase. Why uric acid may behave as a “final common pathway” marker in diabetic AMI In summary, the short-term complication trajectory in our group is clear: hyperuricemia leads to increased Killip classification, resulting in left ventricular dysfunction, heart failure, and ultimately mortality, with hyperglycemia and dyslipidaemia exacerbating severity and complication rates. Uric acid is mechanistically associated with xanthine oxidase activity, oxidative stress, endothelial dysfunction, inflammation, renal impairment, and the biology of metabolic syndrome—elements that are particularly exacerbated in type 2 diabetes. This may elucidate why, in our investigation, urate was not just correlated with a single outcome but was monitored across clinical severity (Killip), structural dysfunction (echocardiography), clinical complications (heart failure), and definitive outcomes (mortality). Extensive observational data indicates that urate serves as a predictor of myocardial infarction/heart failure risk and negative outcomes, whereas cohorts focused on acute coronary syndrome have further prognostic value when urate is included into known risk stratification methods. Beyond the fundamental linkages, the most effective interpretation of our data is to consider uric acid, glucose, and cholesterol as three perspectives into a unified pathobiological framework rather than three distinct laboratory anomalies. In type 2 diabetes, the initial environment is characterised by insulin resistance, persistent low- grade inflammation, endothelial dysfunction, and microvascular damage. An acute myocardial infarction serves as a "stress test" for the entire system, characterised by a spike in catecholamines, an increase in cortisol, activation of inflammatory cytokines, heightened platelet reactivity, and transitory renal hypoperfusion, all occurring nearly simultaneously. In that context, increased uric acid frequently indicates not just purine metabolism but also a wider oxidative- inflammation load, and it may therefore coincide with the processes that enlarge infarct size, exacerbate myocardial shock, and trigger early pump failure. This elucidates why uric acid may function as a significant marker, even in the absence of being the primary causative factor, and why it correlates strongly with the clinical severity phenotype observed at the bedside. Our findings indicate that metabolic stabilisation is crucial to cardiac stabilisation within acute treatment pathways. This encompasses the early identification of dehydration as opposed to congestion (which can be challenging in diabetics experiencing osmotic diuresis and concurrent heart failure), prudent fluid administration, prompt diuretic intervention upon the onset of pulmonary oedema, and the prevention of iatrogenic exacerbation due to excessive fluid intake or postponed management of congestion. It also facilitates meticulous medication reconciliation, as certain pharmaceuticals might affect uric acid levels, renal function, and glucose regulation, necessitating adjustments during acute sickness. An additional topic for in-depth exploration is the prospective function of oxidative stress pathways as a cohesive mechanism. The generation of uric acid is associated with oxidative metabolism, whereas acute hyperglycemia induces oxidative stress via many biochemical pathways. Oxidative stress compromises the endothelium, diminishes nitric oxide levels, enhances vasoconstriction, elevates platelet activity, and exacerbates reperfusion injury. This establishes a unified framework linking metabolic disturbances to increased infarct size, elevated risk of pump failure, and associated consequences. Although we do not directly assess oxidative indicators, the identified clustering of metabolic anomalies and negative outcomes aligns physiologically with an oxidative stress–dominant phenotype. It is pertinent to examine the notion of “infarct size versus clinical expression.” Two individuals may have analogous angiographic results, yet experience markedly divergent clinical outcomes based on metabolic state, microvascular function, and compensatory ability. Our findings corroborate the idea that metabolic variables influence the clinical manifestation of acute myocardial infarction (AMI). This elucidates why certain diabetes patients swiftly advance to severe dyspnoea or shock, while others maintain stability. Prominent metabolic derangements may result in diminished myocardial recovery after ischaemia, prolonging myocardial shocking and contributing to sustained left ventricular dysfunction and an increased heart failure load in the first phase. Ultimately, a prospective discourse can delineate how our findings may influence future research design and enhancements in clinical practice. Future research may involve stratification based on renal function, standardised timing of lipid assessments in relation to symptom onset, continuous glucose monitoring to assess variability, and the inclusion of supplementary metabolic indices (such as HbA1c for chronic glycaemic regulation) to differentiate acute stress hyperglycemia from chronic poor control. Integrating uric acid into existing clinical risk scores or combining it with bedside evaluations and echocardiographic results might produce a practical risk assessment tool specifically designed for diabetic AMI populations. The objective is not to assert that uric acid induces difficulties, but to ascertain its efficacy in enhancing early risk categorisation and facilitating more efficient resource allocation. The comprehensive interpretation of our data indicates that metabolic parameters in diabetes acute myocardial infarction serve as a composite indicator of biological stress, diminished compensatory capacity, and multi-organ susceptibility. This characteristic clinically presents as increased haemodynamic severity, enhanced left ventricular dysfunction, and an elevated risk of early consequences. Consequently, our research advocates for a treatment strategy in which metabolic assessment is seen as a fundamental element of early prognostication and management planning for type 2 diabetes patients experiencing acute myocardial infarction, rather than as ancillary information considered post-crisis. Clinical implications from our study (short-term, bedside-usable) Our findings substantiate the use of a straightforward metabolic panel method in diabetic acute myocardial infarction: 1. Serum uric acid may function as an early indicator to identify persons predisposed to elevated Killip class and the onset of heart failure. 2. When hyperuricemia is present alongside hyperglycemia and dyslipidaemia, our findings indicate a significantly elevated prevalence of Killip III–IV and heart failure, indicating that this subgroup should be classified as very high risk for short-term consequences. 3. The findings from our cohort emphasise that early imaging and proactive heart failure prevention and therapy are crucial when urate levels are elevated. 4. The interpretation of cholesterol in acute myocardial infarction should be contextual; admission levels may indicate acute-phase effects, while dyslipidaemia is essential for subsequent prevention and risk management. Strengths • Comprehensive examination of several metabolic indicators (uric acid, blood glucose, cholesterol) concurrently rather than separately, facilitating the evaluation of their collective influence on short-term prognosis in acute myocardial infarction with type 2 diabetes. • Incorporation of a control (normouricemic) group, facilitating a more precise comparison of results and enhancing internal validity. • Utilisation of clinically pertinent hard endpoints, including Killip class, heart failure, arrhythmias, left ventricular systolic dysfunction, and death, which directly indicate bedside severity. • Evaluation of echocardiographic left ventricular function, establishing an objective relationship between biochemical anomalies and structural/functional cardiac dysfunction. • Equitable sex distribution enhances the generalisability among male and female diabetes patients. • The findings are practical and relevant at the bedside, utilising commonly available laboratory measures without the necessity for sophisticated biomarkers. Limitations • Single-center study with a limited sample size, perhaps restricting generalisability to larger groups. • Limited to short-term follow-up, hence confining conclusions to in-hospital and early results, without providing insight into long-term prognosis. • Renal function and the effects of medications (e.g., diuretics, urate- lowering agents, statins) were not independently adjusted, potentially affecting the correlations between uric acid and outcomes. • Metabolic data were measured at a single time point; dynamic fluctuations, such as glucose variability and serial uric acid levels, were not evaluated. • Cholesterol levels were assessed during the acute phase of myocardial infarction, perhaps affected by inflammatory reactions and may not represent baseline lipid state. • The absence of multivariable adjustment restricts the capacity to determine the independent predictive significance of any metabolic component. Future Directions • Extensive multicenter prospective studies are required to validate findings across varied demographics and healthcare environments. • Integration of long-term follow-up to evaluate effects on recurrent myocardial infarction, chronic heart failure, and survival rates. • Assessment of dynamic metabolic alterations, encompassing sequential glucose, uric acid, and lipid evaluations, and their correlation with results. • Incorporation of metabolic markers into risk prediction models in conjunction with existing clinical ratings to enhance early prognostication in diabetic acute myocardial infarction. • Research investigating the potential of targeted metabolic optimisation (e.g., regulated glycemia, urate-lowering interventions) to enhance short- term outcomes. • Incorporation of supplementary indicators, including HbA1c, renal biomarkers, and inflammatory indices, to more effectively differentiate acute stress impacts from chronic metabolic load.

This study suggests that blood uric acid is a significant and clinically pertinent predictive indicator in individuals with type 2 diabetes mellitus experiencing acute myocardial infarction. Increased uric acid levels were consistently linked to a higher Killip class, a larger prevalence of heart failure, diminished left ventricular systolic performance, an elevated occurrence of arrhythmias, and increased short-term mortality. The coexistence of hyperuricemia, hyperglycemia, and dyslipidaemia delineates a grouping of individuals with much worse short-term outcomes, emphasising the necessity of considering metabolic abnormalities as a cohesive risk profile rather than as separate laboratory results. Regular evaluation of these metabolic indicators upon admission might provide early risk categorisation, enhanced surveillance, and prompt intervention, thereby improving short-term outcomes in diabetes individuals experiencing acute myocardial infarction.

Conflict of Interest: None

Funding Support: Nil